REFERENCES
- Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12(2)308–329
- Garnacho-Montero J, Ortiz-Leyba C, Garcia Garmendia JL, Jimenez F. Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate. Clin Infect Dis 1998; 26(4)1016
- Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26(6)1383–1396
- Rowles DM, Fraser SL. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review. Clin Infect Dis 1999; 29(6)1564–1565, [CROSSREF]
- Ferreira E, Perreault MM. Hypertension exacerbated by amphotericin B administration. Ann Pharmacother 1997; 31(11)1407–1408
- Le Y, Rana KZ, Dudley MN. Amphotericin B-associated hypertension. Ann Pharmacother 1996; 30(7-8)765–767
- Omizo MK, Bryant RE, Loveless MO. Amphotericin B‐induced malignant hypertension. Clin Infect Dis 1993; 17(4)817–818
- Katz BZ, Cohn RA. Amphotericin B and hypertension. Pediatr Infect Dis J 1994; 13(9)839–840
- Dukes CS, Perfect JR. Amphotericin B-induced malignant hypertensive episodes. J Infect Dis 1990; 161(3)588
- Sawaya BP, Weihprecht H, Campbell WR, et al. Direct vasoconstriction as possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991; 87(6)2097–2107
- Potter M. Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemother 2005; 56(suppl 1)i49–i54, [CROSSREF]